Biomea Fusion (BMEA) to Release Quarterly Earnings on Thursday

Biomea Fusion (NASDAQ:BMEA) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Trading Up 5.6 %

NASDAQ:BMEA opened at $2.06 on Thursday. The firm has a market capitalization of $77.40 million, a PE ratio of -0.51 and a beta of -0.07. Biomea Fusion has a 1 year low of $1.53 and a 1 year high of $13.43. The firm’s fifty day simple moving average is $2.45 and its 200 day simple moving average is $5.07.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Oppenheimer set a $10.00 price objective on Biomea Fusion in a research note on Monday, March 24th. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of Biomea Fusion in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Biomea Fusion in a research report on Monday, March 31st. Finally, Barclays reduced their price target on shares of Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, April 2nd. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Biomea Fusion currently has a consensus rating of “Buy” and an average target price of $23.91.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.